In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA – Research Report), with a price target of $11.50.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors surrounding Innate Pharma’s promising pipeline and strategic developments. The potential of IPH4502, a Nectin-4 targeting ADC, is highlighted as a key differentiator in the treatment of solid tumors, particularly due to its ability to potentially overcome resistance seen in current therapies. This compound is being evaluated in a Phase 1 study for various cancers, including breast, lung, and ovarian, which may demonstrate better efficacy compared to existing treatments.
Additionally, the development of IPH6501 for B-cell non-Hodgkin’s lymphoma and autoimmune diseases is another promising aspect, with initial data expected in late 2025. The breakthrough designation for lacutamab in treating Sézary syndrome further underscores the company’s potential for accelerated approval pathways. Despite a projected net loss for 2025, Innate Pharma’s financial position is deemed stable, with sufficient cash reserves to support operations into mid-2026, providing a solid foundation for ongoing and future clinical developments.